Olaratumab

Drug Profile

Olaratumab

Alternative Names: Anti-PDGFRα mAb 3G3; IMC-3G3; Lartruvo; LY 3012207

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Soft tissue sarcoma
  • Phase I Solid tumours
  • No development reported Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 19 Oct 2016 Registered (accelerated approval) for Soft tissue sarcoma (Late-stage disease, Combination therapy) in USA (IV) - First global approval
  • 19 Oct 2016 Safety and efficacy data from a phase I/II trial in Soft tissue sarcoma (Late-stage disease, Combination therapy) released by Eli Lilly ,
  • 07 Oct 2016 Efficacy data from a phase I/II trial in Soft tissue sarcoma presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top